PIOL suitable for myopic eyes

Article

The acrylic angle-supported phakic IOL (PIOL) provides moderate one-year rotational stability, making it a successful treatment option for myopic eyes, claims a new paper.

The acrylic angle-supported phakic IOL (PIOL) provides moderate one-year rotational stability, making it a successful treatment option for myopic eyes, claims a new paper.

Dr Omid Kermani et al., Augenklinik am Neumarkt, Cologne, Germany, evaluated the rotational stability of the PIOL 12 months after implantation in fifty eyes of 28 patients with myopia. Digital overlay of the ocular photographs, taken within two weeks of implantation, were used to assess IOL rotation.

The secondary outcomes included spherical equivalent, refractive sphere and cylinder, uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA). All measurements were analysed preoperatively and three months after implantation.

All patients underwent successful IOL implantation and follow-up. The outcomes presented a mean 12-month rotation of 11º and only 2% of eyes required additional laser adjustment by month 12, due to corneal astigmatism.

Outcomes improved at the three-month follow-up, with spherical equivalent at 0.35 ± 0.79 D, spherical refraction at 0.04 ± 0.82 D and cylindrical refraction at −0.77 ± 0.91 D.

Overall, the lens effectively corrects myopia but the rotation means it is unsuitable for cylinder correction.

The abstract can be viewed in the latest issue of the Journal of Refractive Surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.